全国同城凤凰楼信息茶楼_51pcmc品茶2024官网_全国兼职凤凰楼信息

Biography

Dr. ZHOU was graduated with his Master’s degree in Huazhong Agricultural University (2000), and PhD from Shanghai Jiao Tong University (2005), then worked at Chinese National Human Genome Center at Shanghai (CHGC). While at Shanghai Institute of Materia Medica (SIMM, 2006-present), he served as associate professor (2009), professor (2015) and Principal Investigator (2023), specialized in innovative drugs discovery research for hematologic malignancies and invented several therapeutics that are moving to the clinic.

EDUCATION

2001.03-2005.04 PhD in Biology, Shanghai Jiao Tong University, China

1994.09-2000.06 B.S. in Biology, Huazhong Agricultural University, China

WORK EXPERIENCE

2023.05-present Professor, Metabolic Disease Research Center, SIMM

2015.10-2023.04 Professor, Metabolic Disease Research Center, SIMM

2014.04-2015.04 Visiting Scholar, UTHealth School of Biomedical Informatics (SBMI), Houston, USA

2009.10-2015.09 Associate Professor, Metabolic Disease Research Center, SIMM

2006.08-2009.09 Assistant Professor, Metabolic Disease Research Center, SIMM

2005.04-2006.07 Assistant Professor, CHGC

Research Directions

Innovative drug discovery and personalized research focused on proteostasis.

Achievements

1. Published more than 50 research articles in SCI-cited journals, including Nat. Communications., Leukemia, Acta Pharmacol.Sin., Angew. Chem. Int. Ed, J. Med.Chem. et al.

2. Applied for nearly 150 domestic and international patents (55 have been authorized).

3. Four anti-cancer drug candidates entered clinical trials, two IND and five PCC molecules are in systematic preclinical studies.

Publications

1. Targeting C/EBPa overcomes primary resistance and improves the efficacy of FLT3 inhibitors in acute myeloid leukaemia. Wang HL, Luo GH, Hu XB, Xu GY, Wang T, Liu MM, Qiu XH, Li JN, Fu JF, Feng B, Tu YT, Kan WJ, Wang C, Xu R, Zhou YB*, Yang JM*, Li J*. Nat Commun. 2023,14:1882.

2. Dual inhibition of CHK1/FLT3 enhances cytotoxicity and overcomes adaptive and acquired resistance in FLT3-ITD acute myeloid leukemia. Jiang KL, Li XM, Wang C, Hu XB, Wang PP, Tong LX, Tu YT, Chen BJ, Jing TT, Wang T, Wang HL, Han YB, Gui RZ, Yang JM, Liu T*, Li J*, Zhou YB*. Leukemia. 2023, 37, 539–549.

3. Discovery of toxoflavin, a potent IRE1α inhibitor acting through structure-dependent oxidative inhibition. Jiang KL, Liu CM, Nie LT, Jiang HN, Xu L, Zhang KZ, Fan LX, Gao AH, Lin LL, Wang XY, Tan MJ, Zhang QQ*, Zhou YB*, Li J*. Acta Pharmacol Sin. 2023, 44(1), 234–243.

4. Discovery of a potent and selective degrader for USP7. Pei Y, Fu JF, Shi YK, Zhang MM, Luo GH, Luo XM, Song N, Mi T, Yang YX, Li J*, Zhou YB*, Zhou B*. Angew. Chem. Int. Ed. 2022, 61 (33): e202204395.

5. Identification of 2-aminopyrimidine ferivatives as FLT3 kinase inhibitors with high selectivity over c-KIT. Tong LX, Wang PP, Li X, Dong XW, Hu XB, Wang C, Liu T*, Li J*, Zhou YB*. J Med Chem. 2022, 65 (4): 3229-3248. 

6. Downregulation of c-Myc expression confers sensitivity to CHK1 inhibitors in hematologic malignancies. Jiang KL, Tong LX, Wang T, Wang HL, Hu XB, Xu GY, Jin TT, Kan WJ, Xu L, Li JN, Zhang KX, Song N, Liu JY, Zhang MM, Wu WB, Xiang YQ, Gao AH, Hu YZ, Zhou YB*, Liu T*, Yang JM*, Li J*. Acta Pharmacol Sin. 2022, 43 (1): 220-228. 

7. Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma. Zhou YB#, Zhang YM#, Huang HH#, Shen LJ, Han XF, Hu XB, Yu SD, Gao AH, Sheng L, Su MB, Wei XL, Zhang Y, Zhang YF, Gao ZW, Chen XY, Nan FJ*, Li J*, Hou J*. Acta Pharmacol Sin. 2022, 43 (4): 1091-1099.

8. Structural feature analyzation strategies toward discovery of orally bioavailable PROTACs of bruton's tyrosine kinase for the treatment of lymphoma. Zhang JY, Che JX, Luo XM, Wu MF, Kan WJ, Jin YH, Wang HL, Pang A, Li C, Huang WH, Zeng SX, Zhuang WH, Wu YZ, Xu YJ, Zhou YB*, Li J*, Dong XW*. J Med Chem. 2022, 65 (13):9096-9125. 

9. Structure-activity relationship study of indolin-5-yl-cyclopropanamine derivatives as selective lysine specific demethylase 1 (LSD1) inhibitors. Li CP, Su MB, Zhu W, Kan WJ, Ge TP, Xu GY, Wang SN, Sheng L, Gao F, Ye YF, Wang J, Zhou YB*, Li J*, Liu H*. J Med Chem. 2022, 65 (5): 4335-4349. 

10. Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma. Zhang XT, Hu XB, Wang HL, Kan WJ, Xu L, Wang ZJ, Xiang YQ, Wu WB, Feng B, Li JN, Gao AH, Dong TC, Xia CM, Zhou YB*, Li J*. Acta Pharmacol Sin. 2021, 42 (5): 814-823.